Squamous Cell Carcinoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal Chromoendoscopy
Conditions: Esophageal Squamous Cell Carcinoma Interventions: Drug: 1% Lugol ' s iodine solution; Drug: 5% Lugol ' s iodine solution Sponsors: Xijing Hospital of Digestive Diseases; Ankang Central Hospital; The First Affiliated Hospital of ShiheziI University; Xi ' an International Medical Center Hospital; Air Force 986 Hospital; Xianyang Central Hospital (the second people ' s Hospital of Xianyang City) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 3, 2023 Category: Research Source Type: clinical trials

Phase 2 Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Conditions: Neoplasms, Head and Neck Interventions: Drug: Dostarlimab; Drug: Belrestotug; Drug: GSK6097608 Sponsors: GlaxoSmithKline Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials

PBI-MST-01(NCT04541108) Substudy TAK-02: Intratumoral Microdosing of TAK-676 in HNSCC
Conditions: Head and Neck Squamous Cell Carcinoma Interventions: Drug: TAK-676; Drug: Carboplatin; Drug: 5-FU; Drug: Paclitaxel; Combination Product: TAK-676 + Carboplatin; Combination Product: Carboplatin + Paclitaxel; Combination Product: Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + 5-FU; Combination Product: TAK-676 + Carboplatin + Paclitaxel Sponsors: Presage Biosciences; Takeda Completed (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 2, 2023 Category: Research Source Type: clinical trials

Identification of Individual Histological and Blood Markers in Patients With Recurrent or Metastatic Upper Aerodigestive Tract Squamous Cell Carcinoma in Response to Immunotherapies
Conditions: Squamous Cell Carcinoma of the Oropharynx Interventions: Procedure: Tumor Biopsy Sponsors: Fondation H ôpital Saint-Joseph Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Risk Factors of Relapse in Esophageal Squamous Cell Cancers Who Achieve PCR to Neoadjuvant Chemoradiotherapy
Conditions: Esophageal Cancer Interventions: Other: follow up Sponsors: Sun Yat-sen University Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 29, 2023 Category: Research Source Type: clinical trials

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Intervention: Drug: Tislelizumab Sponsor: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

People Living With HIV, Oral and Oropharyngeal Cancer, and Health Equity
Conditions: HIV Infections; Oral Squamous Cell Carcinoma; Oropharyngeal Squamous Cell Carcinoma Interventions: Other: Group Meeting (Focus Group); Other: Questionnaires Sponsors: University of California, San Francisco; National Institute of Dental and Craniofacial Research (NIDCR) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma
Conditions: Esophageal Squamous Cell Carcinoma; Neoadjuvant Chemoimmunotherapy; Adjuvant Therapy Interventions: Drug: Tislelizumab Sponsors: Guo Xufeng Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 27, 2023 Category: Research Source Type: clinical trials

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Condition: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Intervention: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsor: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Study of ALE.C04 in Patients With Head and Neck Cancer
Conditions: Head and Neck Cancer; Head and Neck Squamous Cell Carcinoma Interventions: Drug: ALE.C04; Drug: Pembrolizumab Sponsors: Alentis Therapeutics AG Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors
Conditions: PARP Inhibitor for Esophageal Squamous Cell Carcinoma Interventions: Drug: Fluzoparib monotherapy or Fluzoparib with Camrelizumab(Only non-small cell lung cancer arm) ,or Fluzoparib combined with capecitabine (only rectal cancer arm)) Sponsors: Chongqing University Cancer Hospital Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 26, 2023 Category: Research Source Type: clinical trials

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC
Condition: Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) Interventions: Drug: Pembrolizumab; Drug: Carboplatin; Drug: Paclitaxel Sponsor: Dan Zandberg Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - September 25, 2023 Category: Research Source Type: clinical trials